Published in HPB (Oxford) on July 19, 2011
Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol (2014) 0.94
Monitoring for post-transplant hepatocellular carcinoma recurrence. HPB (Oxford) (2012) 0.76
Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria. Indian J Surg (2014) 0.75
Late recurrence of hepatocellular carcinoma after liver transplantation. Hepatoma Res (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl (2005) 2.56
Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg (2007) 2.12
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl (2005) 2.04
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer (2009) 1.02
Liver transplantation for hepatocellular carcinoma: the Baylor experience. J Hepatobiliary Pancreat Sci (2009) 0.82
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol (2006) 2.12
Procurement of liver and pancreas allografts in donors with replaced/accessory right hepatic arteries. Transplantation (2004) 2.01
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer (2010) 1.87
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol (2012) 1.71
Robotic compared with laparoscopic sacrocolpopexy: a randomized controlled trial. Obstet Gynecol (2014) 1.66
Hepatic allograft-derived Kupffer cells regulate T cell response in rats. Liver Transpl (2003) 1.65
Concomitant surgery with laparoscopic live donor nephrectomy. Am J Transplant (2003) 1.62
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg (2011) 1.60
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg (2003) 1.54
Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: a matched, case-controlled study. Liver Transpl (2002) 1.52
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology (2015) 1.48
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology (2013) 1.46
Choledocho-choledochostomy in deceased donor liver transplantation. J Gastrointest Surg (2008) 1.39
Persistent sexual dysfunction impairs quality of life after cardiac transplantation. J Sex Med (2010) 1.38
Choice of instruments for assisted vaginal delivery. Cochrane Database Syst Rev (2010) 1.35
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology (2012) 1.19
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol (2012) 1.16
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol (2013) 1.12
Video-microscopy for use in microsurgical aspects of complex hepatobiliary and pancreatic surgery: a preliminary report. HPB (Oxford) (2011) 1.10
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol (2012) 1.05
Antibodies to thyroid peroxidase arise spontaneously with age in NOD.H-2h4 mice and appear after thyroglobulin antibodies. Endocrinology (2010) 1.04
Murine model of Hirschsprung-associated enterocolitis. I: phenotypic characterization with development of a histopathologic grading system. J Pediatr Surg (2010) 1.04
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology (2013) 1.03
Management of chronic hepatitis B in pregnancy. Clin Liver Dis (2010) 1.03
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol (2011) 0.98
Murine model of Hirschsprung-associated enterocolitis II: Surgical correction of aganglionosis does not eliminate enterocolitis. J Pediatr Surg (2010) 0.97
Reactive oxygen species are essential mediators in antigen presentation by Kupffer cells. Immunol Cell Biol (2005) 0.97
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl (2013) 0.96
Diaphragmatic hernia after right donor and hepatectomy: a rare donor complication of partial hepatectomy for transplantation. Hepatobiliary Pancreat Dis Int (2006) 0.95
Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species. Am J Physiol Gastrointest Liver Physiol (2004) 0.94
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93
A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting. Qual Life Res (2012) 0.93
Hepatic encephalopathy. Clin Liver Dis (2012) 0.93
Exploring potential use of internet, E-mail, and instant text messaging to promote breast health and mammogram use among immigrant Hispanic women in Los Angeles County. Am Surg (2013) 0.92
The utility of TIPS in the management of Budd-Chiari syndrome. Ann Surg (2005) 0.90
Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int (2010) 0.89
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-alpha. Hepatology (2005) 0.89
Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol (2013) 0.89
Normal and variant arterial supply of the liver and gallbladder. Pediatr Transplant (2003) 0.88
Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol (2007) 0.88
Interaction of CD44 and hyaluronic acid enhances biliary epithelial proliferation in cholestatic livers. Am J Physiol Gastrointest Liver Physiol (2008) 0.88
Splenic lymphopenia in the endothelin receptor B-null mouse: implications for Hirschsprung associated enterocolitis. Pediatr Surg Int (2011) 0.87
Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transplant (2004) 0.87
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med (2015) 0.87
Perceived impact of the disclosure of a schizophrenia diagnosis. Community Ment Health J (2010) 0.87
Emerging role of transplantation for primary liver cancers. Cancer J (2004) 0.87
Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation (2014) 0.86
A preliminary study of the effects of repeated massage on hypothalamic-pituitary-adrenal and immune function in healthy individuals: a study of mechanisms of action and dosage. J Altern Complement Med (2012) 0.86
The effect of burn injury on CD8+ and CD4+ T cells in an irradiation model of homeostatic proliferation. J Trauma (2006) 0.86
A disease-based comparison of liver transplantation outcomes. Am Surg (2009) 0.85
Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol (N Y) (2011) 0.85
Early recognition of risk factors for adverse outcomes during hospitalization among Medicare patients: a prospective cohort study. BMC Geriatr (2013) 0.85
Successful transplantation of cadaveric polycystic liver: case report and review of the literature. Transplantation (2006) 0.84
Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. Int J Hepatol (2012) 0.84
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int (2013) 0.84
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm (2005) 0.84
Attitudes, psychology, and risk taking of potential live kidney donors: strangers, relatives, and the general public. Am J Transplant (2005) 0.83
Hepatic reticuloendothelial system dysfunction after ischemia-reperfusion: role of P-selectin-mediated neutrophil accumulation. Liver Transpl (2003) 0.83
Hepaticojejunostomy using short-limb Roux-en-Y reconstruction. JAMA Surg (2013) 0.83
Managing Obstetric Emergencies and Trauma (MOET) structured skills training in Armenia, utilising models and reality based scenarios. BMC Med Educ (2002) 0.83
Juxta-caval hepatic angiomyolipoma masquerading as hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int (2003) 0.82
Immunomodulatory Role of Kupffer Cell in Liver Allografts. Comp Hepatol (2004) 0.82
Trimming of damaged 3' overhangs of DNA double-strand breaks by the Metnase and Artemis endonucleases. DNA Repair (Amst) (2013) 0.82
FDG PET/CT as a prognostic test after 90Y radioembolization in patients with metastatic hepatic disease. Clin Nucl Med (2012) 0.82
Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma. Thyroid (2013) 0.81
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response. Curr Med Res Opin (2010) 0.81
WITHDRAWN: Vacuum extraction versus forceps for assisted vaginal delivery. Cochrane Database Syst Rev (2010) 0.81
Current status of liver transplantation for hepatitis B virus. Clin Liver Dis (2011) 0.81
A simple algorithm for drain management after pancreaticoduodenectomy. Am Surg (2012) 0.81
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology (2009) 0.80
Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord (2012) 0.80
Detection and characterization of hepatic engraftment of embryonic stem derived cells by fluorescent stereomicroscopy. J Surg Res (2007) 0.80
Laparoscopic procurement model for living donor liver transplantation. Clin Transplant (2003) 0.80
Current surgical management of infected pancreatic necrosis. Am Surg (2010) 0.79